Search results for "PSYCHOSIS"

showing 10 items of 324 documents

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for mul…

2016

Abstract Background Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports. We aimed to systematically review the efficacy and safety of AceI and memantine across multiple outcome dimensions in BD. Methods Systematic PubMed and SCOPUS search until 04/17/2015 without language restrictions. Included were randomized controlled trials (RCTs), open label studies and case series of AceI or memantine in BD patients reporting quantitative data on depression, mania, psychotic symptoms, global functioning, or cognitive performance. We summarized results using a best-…

Malelaw.inventionpsychosis.0302 clinical medicinePiperidinesRandomized controlled triallawDonepezilDonepezilRandomized Controlled Trials as Topicbipolar disorderClinical Trials as TopicEvidence-Based MedicineDepressionMemantineMiddle AgedManiaPsychiatry and Mental healthClinical PsychologyTreatment Outcomeacetylcholinesterase inhibitorsdepressionIndansFemalemedicine.symptomPsychologyManiamedicine.drugAdultmedicine.medical_specialtyBipolar disorderPlaceboBipolar disorder Acetylcholinesterase inhibitors Memantine Depression Mania Psychosis03 medical and health sciencesmaniaMemantineInternal medicinemedicineGalantamineHumansBipolar disorderAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis.PsychiatryDepressive DisorderGalantaminePsychosismedicine.disease030227 psychiatryAcetylcholinesterase inhibitorsMoodPsychotic DisordersAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis; Psychiatry and Mental Health; Clinical PsychologyCase-Control StudiesmemantineCholinesterase InhibitorsExcitatory Amino Acid Antagonists030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

Cannabis use in male and female first episode of non-affective psychosis patients: long-term clinical, neuropsychological and functional differences

2017

BACKGROUND: Numerous studies show the existence of a high prevalence of cannabis use among patients with psychosis. However, the differences between men and women who debut with a first episode of psychosis (FEP) regarding cannabis use have not been largely explored. The aim of this study was to identify the specific sex factors and differences in clinical evolution associated with cannabis use. METHOD: Sociodemographic characteristics at baseline were considered in our sample of FEP patients to find differences depending on sex and the use of cannabis. Clinical, functional and neurocognitive variables at baseline, 1-year, and 3-years follow-up were also explored. RESULTS: A total of 549 pa…

Malelcsh:MedicineSocial Sciences[ SCCO.PSYC ] Cognitive science/PsychologyNeuropsychological TestsDrug UsersCognitionLearning and Memory0302 clinical medicineMedicine and Health SciencesPsychologyYoung adultlcsh:ScienceFirst episodeMultidisciplinarybiologyNeuropsychologyCognitionAddicts3. Good healthBehavioral PharmacologySchizophrenia[ SCCO.NEUR ] Cognitive science/Neuroscience[SCCO.PSYC]Cognitive science/Psychology[SCCO.PSYC] Cognitive science/PsychologyFemaleResearch ArticleAdultPsychosismedicine.medical_specialtyCognitive NeurosciencePsicosiAddictionMarijuana SmokingYoung Adult03 medical and health sciencesMemoryRecreational Drug UseCànnabisMental Health and PsychiatrymedicineHumansFactors sexuals en les malaltiesWorking MemoryPsychiatryCannabisPharmacologybusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/Neurosciencelcsh:RCognitive PsychologyBiology and Life SciencesPsychosesmedicine.diseasebiology.organism_classification030227 psychiatryPsychotic DisordersSchizophreniaCognitive ScienceSex factors in diseaselcsh:QCannabisbusinessNeurocognitive030217 neurology & neurosurgeryNeuroscience
researchProduct

Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis.

2003

AbstractA female patient with multiple sclerosis (MS) suffered from an acute psychotic disorder after taking distigmine bromide for detrusor dysfunction. She showed a dramatic relief of her symptoms after the medication, distigmine bromide, was stopped. Distigmine is not supposed to penetrate the blood-brain barrier (BBB). However, in MS patients a leakage of the BBB could be hypothesized.

Malemedicine.medical_specialtyPsychosisMultiple Sclerosismedicine.medical_treatmentPyridinium CompoundsSuicide AttemptedBlood–brain barrierPsychoses Substance-InducedCentral nervous system diseasechemistry.chemical_compoundBromidemedicineHumansDistigminePsychiatric Status Rating ScalesChemotherapybusiness.industryMultiple sclerosisUrinary Retentionmedicine.diseasePathophysiologySurgeryPsychiatry and Mental healthmedicine.anatomical_structurechemistryParasympathomimeticsAnesthesiaFemalebusinessmedicine.drugEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings from the Multinational EU-GEI Study

2021

The influence of psychosocial stressors on psychosis risk has usually been studied in isolation and after the onset of the disorder, potentially ignoring important confounding relationships or the fact that some stressors that may be the consequence of the disorder rather than preexisting. The study of subclinical psychosis could help to address some of these issues. In this study, we investigated whether there was (i) an association between dimensions of subclinical psychosis and several psychosocial stressors including: childhood trauma, self-reported discrimination experiences, low social capital, and stressful life experiences, and (ii) any evidence of environment-environment (ExE) inte…

Malestressful life eventsSchizotypypositive subclinical symptomEthnic groupSocial Environmentsubclinical psychosispositive subclinical symptoms0302 clinical medicineAdverse Childhood ExperiencesSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.SINTOMAS PSÍQUICOSsubclinical psychosi10. No inequalityCOMMUNITY ASSESSMENTSubclinical infectionGENERAL-POPULATIONpsychotic symptomDepressionConfoundingSocial Discriminationdepressive subclinical symptomstressful life eventETHNIC-GROUPS3. Good healthPsychiatry and Mental healthNEIGHBORHOOD CHARACTERISTICSADULT PSYCHIATRIC-DISORDERSpsychotic symptomsAdverse Childhood ExperienceFemalepsychosocial stressPsychologyPsychosocialHumanClinical psychologynegative subclinical symptompsychosocial streAdultPsychosisSiblingLIFE EVENTSschizotypyPsychotic Disorder03 medical and health sciencesCommunity Assessment of Psychic Experiences (CAPE)THREATENING EXPERIENCESmedicineHumansEuropean UnionSiblingSettore MED/25 - Psichiatriachildhood traumaSiblingsStressormedicine.diseasePERCEIVED DISCRIMINATIONnegative subclinical symptoms030227 psychiatryPSYCHOMETRIC PROPERTIESPsychotic Disorders[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthdis criminationsocial capitaldepressive subclinical symptomsStress Psychological030217 neurology & neurosurgeryRegular Articlesdiscrimination
researchProduct

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study

2021

The work was supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital NHS Foundation Trust to DQ; DFG Heisenberg professorship (no. 389624707) to UR. National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by t…

Marijuana AbuseIMPACTPoison controlCannabis usecannabis-associated psychosis0302 clinical medicineSCHIZOPHRENIASettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.health care economics and organizationsApplied PsychologyRISKOUTCOMESbiologyHuman factors and ergonomics/dk/atira/pure/subjectarea/asjc/2700/2738psychopathologyCannabis use; cannabis-associated psychosis; first episode psychosis; psychopathology; psychotic experiences; symptom dimensions3. Good healthPsychiatry and Mental healthSchizophreniaHEALTHPsychopathologyPsychosismedicine.medical_specialtyDISORDERSeducationsymptom dimensions03 medical and health sciencesInjury preventionfirst episode psychosismedicineHumanspsychotic experiencesPsychiatryABUSESettore MED/25 - PsichiatriaSUBSTANCE USEMETAANALYSISCannabisbusiness.industryCase-control studyOriginal Articlesmedicine.diseasebiology.organism_classification030227 psychiatrypsychotic experiencePsychotic Disordersfirst episode psychosiCase-Control StudiesONSETGene-Environment Interaction/dk/atira/pure/subjectarea/asjc/3200/3202Cannabisbusinesscannabis-associated psychosi030217 neurology & neurosurgery
researchProduct

Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study

2021

AbstractBackgroundPerceived discrimination is associated with worse mental health. Few studies have assessed whether perceived discrimination (i) is associated with the risk of psychotic disorders and (ii) contributes to an increased risk among minority ethnic groups relative to the ethnic majority.MethodsWe used data from the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2, a population-based case−control study of incident psychotic disorders in 17 catchment sites across six countries. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) for the associations between perceived discrimination and psychosis using mixed-…

Mediation (statistics)LIFE EVENTSMIGRATIONPopulationEthnic groupLogistic regressionpsychosiOdds03 medical and health sciences0302 clinical medicineMINORIAS ÉTNICASSCHIZOPHRENIAMedicinepsychosisfirst-episodeeducationCase−controlApplied PsychologyTRAUMACase-control discrimination first-episode minority ethnic group multi-country psychosis psychotic disorderFirst episodemulti-countryeducation.field_of_studyminority ethnic groupCONSEQUENCESbusiness.industryAbsolute risk reductionPATHWAYSOdds ratiopsychotic disorderCase-controlMEDIATION ANALYSIS030227 psychiatryPsychiatry and Mental health[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]HEALTHbusinessCHILDHOOD ADVERSITIES030217 neurology & neurosurgeryDemographydiscrimination
researchProduct

The Open Dialogue Approach to Acute Psychosis: Its Poetics and Micropolitics

2003

In Finland, a network-based, language approach to psychiatric care has emerged, called "Open Dialogue." It draws on Bakhtin's dialogical principles (Bakhtin, 1984) and is rooted in a Batesonian tradition. Two levels of analysis, the poetics and the micropolitics, are presented. The poetics include three principles: "tolerance of uncertainty," "dialogism," and "polyphony in social networks." A treatment meeting shows how these poetics operate to generate a therapeutic dialogue. The micropolitics are the larger institutional practices that support this way of working and are part of Finnish Need-Adapted Treatment. Recent research suggests that Open Dialogue has improved outcomes for young peo…

Mental Health ServicesPatient Care TeamPsychoanalysisPatient care teamSocial PsychologySocial networkbusiness.industrySchizophrenia (object-oriented programming)Follow up studiesAcute PsychosisPsychotherapyClinical PsychologyPsychotic DisordersPoeticsAcute DiseaseHumansPolyphonyPsychologybusinessFinlandSocial Sciences (miscellaneous)LanguageFamily Process
researchProduct

Efavirenz and the CNS: what we already know and questions that need to be answered

2015

The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the multidrug regimens used to treat HIV infection, in accordance with its well-demonstrated antiretroviral efficacy and favourable pharmacokinetics. However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatment selection or to switching of therapy to efavirenz-free regimens in experienced patients. Neurological and neuropsychiatric reactions are the manifestations most frequently experienced by efavirenz-treated patients and range from transitory effects, such as nightmares, dizziness, insomnia, nervousness and lack of conc…

Microbiology (medical)DrugCentral Nervous SystemCyclopropanesPsychosismedicine.medical_specialtyEfavirenzAnti-HIV Agentsmedia_common.quotation_subjectHIV InfectionsPolymorphism Single Nucleotidechemistry.chemical_compoundimmune system diseasesCentral Nervous System DiseasesAntiretroviral Therapy Highly ActivemedicineAnimalsCytochrome P-450 Enzyme InhibitorsHumansPharmacology (medical)Adverse effectIntensive care medicineSuicidal ideationmedia_commonPharmacologybusiness.industryNeurotoxicityvirus diseasesmedicine.diseaseBenzoxazinesCytochrome P-450 CYP2B6Disease Models AnimalInfectious DiseaseschemistryPharmacogeneticsAlkynesReverse Transcriptase Inhibitorsmedicine.symptomCNSEfavirenzbusinessNeurocognitivePharmacogenetics
researchProduct

Positive/negative symptomatology and experimental measures of attention in schizophrenic patients.

1993

In a search for an external validation of the negative syndrome construct and the attentional impairment item on Andreasen's scale, 49 unmedicated schizophrenic patients were administered the Span of Apprehension Test and a Continuous Performance Test with two levels of difficulty. This schizophrenic sample performed significantly more poorly on the attentional tests than a comparable group of 27 healthy control subjects. Depending on the difficulty of the test we found a number of significant correlations between the SANS composite score and the pertaining attentional impairment item on the one hand and experimental indices of attentional functioning on the other hand, which might corrobor…

Negative symptomAdultMalePsychiatric Status Rating ScalesPsychosismedicine.medical_specialtyPsychometricsAdolescentCognitive disorderExternal validationMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologySchizophreniamedicineSchizophreniaHumansAttentionFemaleSchizophrenic PsychologyPsychologyPsychiatryPsychopathology
researchProduct

Substance use, medication adherence and outcome one year following a first episode of psychosis

2016

Both substance use and poor medication adherence are associated with poor outcome in psychosis. To clarify the contributions of substance use and poor medication adherence to poor outcome in the year following a first episode of psychosis, 205 patients were evaluated for use of tobacco, alcohol, cannabis and stimulants at their psychosis onset, and in a 1-year follow-up. Data on medication adherence and symptom remission were also collected. Patients had high rates of overall substance use before (37-65%) and after psychosis onset (45-66%). 44% showed poor medication adherence and 55% did not reach remission from psychosis. Nicotine dependence and cannabis use after psychosis onset signific…

Nicotine dependenceAdultMalePsychosismedicine.medical_specialtyFirst episode psychosisRemissionSubstance-Related DisordersMedication adherenceSubstance useCannabis useMedication AdherenceCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease03 medical and health sciencesYoung Adult0302 clinical medicineSettore M-PSI/08 - Psicologia ClinicamedicineHumansYoung adultCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Psychotic Disorders; Substance-Related Disorders; Treatment Outcome; Young AdultNicotine dependencePsychiatryMedication adherenceSettore MED/25 - PsichiatriaBiological PsychiatryFirst episodebiologyCannabis useMiddle Agedmedicine.diseasebiology.organism_classificationFirst episode psychosi030227 psychiatryTreatment OutcomePsychotic DisordersPsychiatry and Mental HealthAcute DiseaseFemaleCannabisSubstance usePsychology030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct